Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?

Journal of Clinical Pharmacology

Volumn 49, Issue 3, 2009, Pages 281-290

  Van Der Schueren, B J ^a   Lunnon, M W ^b   Laurijssens, B E ^c   Guillard, F ^c   Palmer, J ^b   Van Hecken, A ^a   Depre M ^a   Vanmolkot, F H ^a   De Hoon, J N ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Clinical Pharmacology and Discovery Medicine

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

INOS; Migraine therapy; Pharmacodynamic assay; Pharmacokinetics

Indexed keywords

3 [[2 [(1 IMINOETHYL)AMINO]ETHYL]SYLPHONYL]ALANINE; 3 NITROTYROSINE; GW 273629; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRATE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; FEMALE; HUMAN; MALE; MIGRAINE; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADULT; AREA UNDER CURVE; FEMALE; HALF-LIFE; HUMANS; MALE; MIGRAINE DISORDERS; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; SULFONES; TYROSINE;

EID: 61449239077     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008329548     Document Type: Article

References (34)

1. Alderton WK, Angell AD, Craig C., et al. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 2005 ; 145: 301-312.
2. Thomsen LL, Kruuse C., Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol. 1994 ; 1: 73-80.
3. Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H1-receptor: support for the NO hypothesis of migraine. NeuroReport. 1995 ; 6: 1475-1479.
4. Sarchielli P., Alberti A., Codini M., Floridi A., Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia. 2000 ; 20: 907-918.
5. D'Amico D., Ferraris A., Leone M., et al. Increased plasma nitrites in migraine and cluster headache patients in interictal period: basal hyperactivity of L-arginine-NO pathway? Cephalalgia. 2002 ; 22: 33-36.
6. Lassen LH, Ashina M., Christiansen I., Ulrich V., Olesen J. Nitric oxide synthase inhibition in migraine. Lancet. 1997 ; 349: 401-402.
7. Moncada S., Palmer RMJ, Higgs EA Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 ; 43: 109-142.
8. Sarchielli P., Floridi A., Mancini ML, et al. NF-kappaB activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks. Cephalalgia. 2006 ; 26: 1071-1079.
9. Reuter U., Chiarugi A., Bolay H., Moskowitz MA Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol. 2002 ; 51: 507-516.
10. Volans GN Migraine and drug absorption. Clin Pharmacokinet. 1978 ; 3: 313-318.
11. Aurora SK, Kori SH, Barrodale P., McDonald SA, Haseley D. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006 ; 46: 57-63.
12. Subcomittee Ihsct. Guidelines for controlled trials of drugs in migraine second edition. Cephalalgia. 2000 ; 20: 765-786.
13. Dillon WC, Hampl V., Shultz PJ, Rubins JB, Archer SL Origins of breath nitric oxide in humans. Chest. 1996 ; 110: 930-938.
14. Tsikas D. Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids. Free Radic Res. 2005 ; 39: 797-815.
15. Frost MT, Halliwell B., Moore KP Analysis of free and protein-bound nitrotyrosine in human plasma by a gas chromatography/ mass spectrometry method that avoids nitration artifacts. Biochem J. 2000 ; 345 (pt 3). 453-458.
16. Tom T., Brody M., Valabhji A., Turner L., Molgaard C., Rothrock J. Validation of a new instrument for determining migraine prevalence: the UCSD Migraine Questionnaire. Neurology. 1994 ; 44: 925-928.
17. Dear GJ, Plumb RS, Sweatman BC, et al. Use of directly coupled ion-exchange liquid chromatography-mass spectrometry and liquid chromatography-nuclear magnetic resonance spectroscopy as a strategy for polar metabolite identification. J Chromatogr B Biomed Sci Appl. 2000 ; 748: 295-309.
18. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 ; 171: 912-930.
19. Giovannoni G., Land JM, Keir G., Thompson EJ, Heales SJ Adaptation of the nitrate reductase and Griess reaction methods for the measurement of serum nitrate plus nitrite levels. Ann Clin Biochem. 1997 ; 34 (pt 2). 193-198.
20. Brealey D., Brand M., Hargreaves I., et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002 ; 360: 219-223.
21. Persson MG, Agvald P., Gustafsson LE Detection of nitric oxide in exhaled air during administration of nitroglycerin in vivo. Br J Pharmacol. 1994 ; 111: 825-828.
22. Husain M., Adrie C., Ichinose F., Kavosi M., Zapol WM Exhaled nitric oxide as a marker for organic nitrate tolerance. Circulation. 1994 ; 89: 2498-2502.
23. Marczin N., Riedel B., Royston D., Yacoub M. Intravenous nitrate vasodilators and exhaled nitric oxide. Lancet. 1997 ; 349: 1742.
24. Mehta S., Stewart DJ, Levy RD The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Chest. 1996 ; 109: 1550-1555.
25. Stamler JS, Jaraki O., Osborne J., et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA. 1992 ; 89: 7674-7677.
26. Stewart TE, Valenza F., Ribeiro SP, et al. Increased nitric oxide in exhaled gas as an early marker of lung inflammation in a model of sepsis. Am J Respir Crit Care Med. 1995 ; 151 (pt 1). 713-718.
27. Thomsen LL, Olesen J. Nitric oxide in primary headaches. Curr Opin Neurol. 2001 ; 14: 315-321.
28. Sessa WC The nitric oxide synthase family of proteins. J Vasc Res. 1994 ; 31: 131-143.
29. Lamb NJ, Quinlan GJ, Westerman ST, Gutteridge JM, Evans TW Nitration of proteins in bronchoalveolar lavage fluid from patients with acute respiratory distress syndrome receiving inhaled nitric oxide. Am J Respir Crit Care Med. 1999 ; 160: 1031-1034.
30. Kamisaki Y., Wada K., Ataka M., et al. Lipopolysaccharide-induced increase in plasma nitrotyrosine concentrations in rats. Biochim Biophys Acta. 1997 ; 1362: 24-28.
31. Ho TW, Mannix LK, Fan X., et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008 ; 70: 1304-1312.
32. Akerman S., Williamson DJ, Kaube H., Goadsby PJ Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002 ; 137: 62-68.
33. Hoye K., Laurijssens BE, Harnisch LO, et al. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for twelve weeks in the prohylactic treatment of migraine. Cephalagia. In press.
34. Palmer JE, Guillard FL, Laurijssens BE, Wentz AL, Dixon RM, Williams PM A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalagia. In press.